'Circulating' RNA-based therapies in Cardio-Oncology
- PMID: 35924283
- DOI: 10.1093/eurheartj/ehac407
'Circulating' RNA-based therapies in Cardio-Oncology
Conflict of interest statement
Conflict of interest: C.G.T. has received funding from Amgen and personal fees from Vivalyfe, outside of the submitted work, and is listed as an inventor on two heart failure patents. E.H. and A.G. are founders, shareholders, and advisors of Kither Biotech Srl, a pharmaceutical product company developing PI3K inhibitors for the treatment of respiratory diseases not in conflict with statements made in this article.
Comment on
-
A circular RNA derived from the insulin receptor locus protects against doxorubicin-induced cardiotoxicity.Eur Heart J. 2022 Nov 7;43(42):4496-4511. doi: 10.1093/eurheartj/ehac337. Eur Heart J. 2022. PMID: 35758064 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
